Indeed, the levels of cleaved caspase-3 and PARP were markedly increased in ARID1A-deficient CRC cells following ATR or CHK1 inhibitor treatment (Fig. 2E and F). This evidence concerns the gene CHEK1 and colorectal carcinoma.